A Message from Huge Alerts 
Revenues continue to explode for this growing MedTech firm that just got another price increase from Zack’s Small Cap Research to $23.25! The growing MedTech arena is home to some notable players but one company is uniquely standing out as its revenues explode, purchase orders accelerate, and a price target from Zack’s Small Cap Research continues to move north. This company is changing the skin graft market by using the natural properties of perinatal tissue. Growth is rocketing as management makes smart and aggressive moves. Following 2023, a year of tremendous growth, they recently released its Q1 financial results of $ 41 million that revealed the company’s first positive net income! This company attributes its growth to the successful launch of the company’s Amniowrap2™, an innovative placental-derived allograft product designed to address a broad spectrum of wound applications. A significant factor contributing to this success has been the widespread acceptance and utilization of Amniowrap2™ by medical professionals, underscoring its effectiveness and growing prominence in the healthcare industry. They especially gained momentum in the second half of 2023 when the Centers awarded the company a valuable Q code for its Vendaje AC and AmnioWrap2 products for Medicare and Medicaid Services. Most recently, the company announced that its Healthcare Common Procedure Coding System code for Vendaje AC became effective and that the Center for Medicare Services established national pricing for AmnioWrap2 in all 50 states and territories. Additionally, the company isn’t resting on its success as management recently initiated a clinical trial evaluating Vendaje in diabetic foot ulcers—a market with enormous and growing potential! Learn more about why Zack’s has increased its price target on this company to a whopping $23.25! | 
0 Response to "**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1!"
Post a Comment